Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia. Selective inhibition of the second bromodomain of BET family proteins results in robust antitumor activity in preclinical models of acute myeloid leukemia
收藏NIAID Data Ecosystem2026-03-11 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA615190
下载链接
链接失效反馈官方服务：
资源简介：
Selective inhibition of the second bromodomain of BET family proteins is efficacious in preclinical models of AML Overall design: BRD4 ChIP-Seq under three different treatment conditions, H3K27Ac ChIP-Seq control conditions only.
创建时间：
2020-03-25
